

# Peter Duewell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7581523/publications.pdf>

Version: 2024-02-01

34  
papers

5,980  
citations

279798

23  
h-index

377865

34  
g-index

36  
all docs

36  
docs citations

36  
times ranked

10359  
citing authors

#	ARTICLE	IF	CITATIONS
1	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. <i>Nature Biomedical Engineering</i> , 2021, 5, 1246-1260.	22.5	80
2	OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis. <i>Science Immunology</i> , 2021, 6, .	11.9	19
3	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	33
4	RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. <i>Leukemia</i> , 2020, 34, 1017-1026.	7.2	33
5	Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2101-2112.	4.2	12
6	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 5890-5900.	7.0	31
7	Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. , 2019, 7, 288.		22
8	Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma. <i>Translational Oncology</i> , 2019, 12, 350-360.	3.7	27
9	High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. <i>British Journal of Cancer</i> , 2019, 120, 79-87.	6.4	36
10	Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming. <i>Cell</i> , 2018, 172, 162-175.e14.	28.9	705
11	NLRP3 inflammasome activation in inflammaging. <i>Seminars in Immunology</i> , 2018, 40, 61-73.	5.6	109
12	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2018, 9, 1955.	4.8	24
13	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. <i>Scientific Reports</i> , 2018, 8, 8810.	3.3	13
14	Nlrp3-dependent IL-1 $\beta$ inhibits CD103+ dendritic cell differentiation in the gut. <i>JCI Insight</i> , 2018, 3, .	5.0	22
15	Volcanic Ash Activates the NLRP3 Inflammasome in Murine and Human Macrophages. <i>Frontiers in Immunology</i> , 2017, 8, 2000.	4.8	25
16	A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. <i>Oncolmmunology</i> , 2016, 5, e1189051.	4.6	22
17	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 259-268.	7.2	30
18	Immunotherapy in Tumors. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2015, 112, 809-15.	0.9	31

#	ARTICLE	IF	CITATIONS
19	Strategies to relieve immunosuppression in pancreatic cancer. <i>Immunotherapy</i> , 2015, 7, 363-376.	2.0	30
20	Proapoptotic and Antiapoptotic Proteins of the Bcl-2 Family Regulate Sensitivity of Pancreatic Cancer Cells Toward Gemcitabine and T-Cell-mediated Cytotoxicity. <i>Journal of Immunotherapy</i> , 2015, 38, 116-126.	2.4	24
21	Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. <i>OncImmunology</i> , 2015, 4, e1029698.	4.6	36
22	Induction of immunogenic cell death by targeting RIG-I-like helicases in pancreatic cancer. <i>OncImmunology</i> , 2014, 3, e955687.	4.6	12
23	Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 321-333.	4.2	32
24	RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells. <i>Cell Death and Differentiation</i> , 2014, 21, 1825-1837.	11.2	151
25	Inflammasome-Dependent and -Independent IL-18 Production Mediates Immunity to the ISCOMATRIX Adjuvant. <i>Journal of Immunology</i> , 2014, 192, 3259-3268.	0.8	69
26	Therapeutic Efficacy of Bifunctional siRNA Combining TGF- $\beta$ 1 Silencing with RIG-I Activation in Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 1709-1720.	0.9	130
27	Breaking tumor-induced immunosuppression with 5 $\beta$ -triphosphate siRNA silencing TGF $\beta$ 2 and activating RIG-I. <i>OncImmunology</i> , 2013, 2, e24170.	4.6	20
28	Interleukin-2 Is Frequently Expressed in Small- and Large-Cell Lung Cancer and Promotes Growth in Chemotherapy-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1032-1042.	1.1	62
29	Assessment and Quantification of Crystal-Induced Lysosomal Damage. <i>Methods in Molecular Biology</i> , 2013, 1040, 19-27.	0.9	7
30	Protective and Aggravating Effects of Nlrp3 Inflammasome Activation in IBD Models: Influence of Genetic and Environmental Factors. <i>Digestive Diseases</i> , 2012, 30, 82-90.	1.9	121
31	An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. <i>International Journal of Cancer</i> , 2011, 128, 897-907.	5.1	72
32	ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells. <i>Journal of Immunology</i> , 2011, 187, 55-63.	0.8	105
33	Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. <i>Gut</i> , 2010, 59, 1192-1199.	12.1	687
34	NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. <i>Nature</i> , 2010, 464, 1357-1361.	27.8	3,130